HilleVax, Inc. Expected to Post Q2 2024 Earnings of ($0.82) Per Share (NASDAQ:HLVX)

HilleVax, Inc. (NASDAQ:HLVX) – Investment analysts at Leerink Partnrs increased their Q2 2024 earnings estimates for shares of HilleVax in a research report issued on Tuesday, July 9th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of ($0.82) per share for the quarter, up from their prior forecast of ($0.89). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for HilleVax’s current full-year earnings is ($2.54) per share. Leerink Partnrs also issued estimates for HilleVax’s Q3 2024 earnings at ($0.42) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($2.46) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.21) EPS and FY2027 earnings at ($1.42) EPS.

Several other brokerages have also weighed in on HLVX. Guggenheim lowered shares of HilleVax from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Stifel Nicolaus lowered shares of HilleVax from a “buy” rating to a “hold” rating and decreased their price target for the company from $34.00 to $3.00 in a report on Tuesday. HC Wainwright reiterated a “neutral” rating and set a $2.00 price objective (down previously from $28.00) on shares of HilleVax in a research note on Tuesday. JPMorgan Chase & Co. restated a “neutral” rating and issued a $5.00 target price (down from $24.00) on shares of HilleVax in a research note on Monday, July 8th. Finally, SVB Leerink downgraded HilleVax from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $28.00 to $2.00 in a report on Tuesday. Six investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, HilleVax has a consensus rating of “Hold” and an average price target of $9.20.

HilleVax Stock Performance

HilleVax stock opened at $1.75 on Thursday. HilleVax has a 52 week low of $1.55 and a 52 week high of $20.22. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.11. The stock has a market cap of $87.01 million, a P/E ratio of -0.53 and a beta of 0.78. The stock has a 50 day moving average of $12.56 and a 200-day moving average of $14.41.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.13).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. EntryPoint Capital LLC bought a new position in shares of HilleVax during the 1st quarter valued at about $80,000. Swiss National Bank raised its position in shares of HilleVax by 22.4% during the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after purchasing an additional 7,000 shares during the period. SG Americas Securities LLC purchased a new stake in HilleVax during the fourth quarter valued at about $139,000. Tidal Investments LLC acquired a new stake in shares of HilleVax during the first quarter valued at approximately $207,000. Finally, abrdn plc purchased a new stake in shares of HilleVax in the 4th quarter valued at approximately $433,000. Institutional investors own 86.42% of the company’s stock.

Insider Transactions at HilleVax

In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $14.73, for a total transaction of $88,380.00. Following the sale, the director now directly owns 764,878 shares in the company, valued at approximately $11,266,652.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 12,898 shares of company stock worth $193,766. Company insiders own 71.10% of the company’s stock.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.